SCHEMBL4565065

SCHEMBL4565065

O=C1C(OCCCO)=C(c2cn(CCO)c3ccccc23)C(=O)N1c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCB P05771 1/20 0.47
PRKCA P17252 1/20 0.47
PRKCE Q02156 1/20 0.47
CAMK2D Q13557 3/20 0.45
CDK4 P11802 1/20 0.44
PRKACA P17612 1/20 0.44
PRKACG P22612 1/20 0.44
PRKACB P22694 1/20 0.44
CCND1 P24385 1/20 0.44
GSK3B P49841 4/20 0.44
KDR P35968 2/20 0.44
FLT3 P36888 2/20 0.44
CCNB2 O95067 4/20 0.43
CDK1 P06493 4/20 0.43
CCNB1 P14635 4/20 0.43
CCNB3 Q8WWL7 4/20 0.43
SIRT2 Q8IXJ6 1/20 0.42
CCNT1 O60563 1/20 0.41
CCNA2 P20248 1/20 0.41
CDK2 P24941 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4564844 0.89 CCNB2 (0.58) PRKCBPRKCAPRKCECAMK2DCDK4
SCHEMBL4559548 0.84 GSK3B (0.38) PRKCBPRKCAPRKCECAMK2DCDK4
SCHEMBL4565064 0.81 KDR (0.43) PRKCBPRKCAPRKCECAMK2DCDK4
SCHEMBL4565063 0.75 MAPT (0.41) PRKCBPRKCAPRKCECDK4PRKACA
SCHEMBL4564848 0.72 PRKCA (0.51) PRKCBPRKCAPRKCECAMK2DCDK4
SCHEMBL14522482 0.71 GSK3B (0.69) PRKCBPRKCAPRKCECAMK2DCDK4
SCHEMBL7873644 0.69 PRKACA (0.80) PRKCBPRKCAPRKCECAMK2DCDK4
SCHEMBL28661599 0.69 CCNT1 (0.64) PRKCBPRKCAPRKCECAMK2DCDK4
SCHEMBL28374646 0.68 SIRT2 (0.63) SIRT2
SCHEMBL1128014 0.68 CCNB2 (0.79) PRKCBPRKCAPRKCECAMK2DCDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7608634-B2 Substituted pyrrolines as kinase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2009-10-27 US disclosed
EP-2035408-A1 SULPHUR-CONTAINING CYCLIC UREA DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS Aventis Pharma S.A. (FR) 2009-03-18 EP disclosed
WO-2008000922-A1 SULPHUR-CONTAINING CYCLIC UREA DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS AVENTIS PHARMA S.A. (FR) 2008-01-03 WO disclosed
US-20070213387-A1 Substituted pyrrolines as kinase inhibitors ZHANG HAN-CHENG 2007-09-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213387-A1 Substituted pyrrolines as kinase inhibitors PRKDC, MAP2K2, TTK PRKCB 55/4885PRKCA 59/4885PRKCE 53/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.